Emtricitabine

Medical Advocates
Ethics and Infectious Diseases

Ethical Challenges

Screening/Testing
Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations

National Challenges         Sterilization
Bioterrorism                     Prison Challenges
HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention
Stigma
Physician Reimbursement
Ethics and Disease Challenges and Duties
HIV Cure
Ebola Virus Disease
Executions

Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Emtricitabine(Emtriva)

Main Page

New and Noteworthy
Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada)
Tenofovir Alafenamide/Emtricitabine (Descovy)
Rilpivirine/Emtricitabine/Tenofovir DF
Guidelines
Journal Citations
Conference Citations
Pediatric Indications
Perinatal Indications

ARV Drugs Main Page

Main New/Newsworthy

Home Page

This web page is best viewed by using INTERNET EXPLORER
Last Update: March 18, 2017
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy

March 2017

Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV–1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>.
Post FA, Yazdanpanah Y, Schembri G, et al HIV Clin Trials. 2017 Mar 17:1-6.

February 2017

Emtricitabine + tenofovir alafenamide for the treatment of HIV.
Corado KC, Daar ES.Expert Opin Pharmacother. 2017 Feb 2.

Pediatric Indications

Pharmacokinetics

Journal Papers, Abstracts, and Commentaries